Literature DB >> 18097004

A Th1-recognized peptide P277, when tandemly repeated, enhances a Th2 immune response toward effective vaccines against autoimmune diabetes in nonobese diabetic mice.

Liang Jin1, Aihua Zhu, Yu Wang, Qingmei Chen, Qiyan Xiong, Jianping Li, Yunxiao Sun, Taiming Li, Rongyue Cao, Jie Wu, Jingjing Liu.   

Abstract

Subunit immunogens containing tandemly repeated copies of T and B cell epitopes have been shown to be more immunogenic than the respective immunogen containing only a single copy of the sequence. To investigate whether the increased copies of the Th2-activated peptide sequence will enhance the Th2-like immune response, we compared the cytokine secreted in mice that inoculated with two immunogens containing one or six tandemly repeated copies of a Th2-activated peptide sequence P277. Immunization of mice with a 6xP277 fusion protein elicited much higher levels of Th2-type cytokines and lower Th1-type cytokines than with a fusion protein with one P277 peptide. The data of tandemly repeated peptide P277 potentiate the anti-inflammatory in NOD mice, most likely associated with a Th1 to Th2 cytokine shift specific for the autoimmune T cells, which suggested that application of multiple tandem repeats of a Th2-activated epitope is an efficient method to enhance the anti-inflammatory immune response by shifting the immune response from Th1-like to Th2-like. The subunit immunogens containing tandemly repeated copies of peptide P277 might be effective vaccines against autoimmune diabetes in NOD mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097004     DOI: 10.4049/jimmunol.180.1.58

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Production of double repeated B subunit of Shiga toxin 2e at high levels in transgenic lettuce plants as vaccine material for porcine edema disease.

Authors:  Takeshi Matsui; Eiji Takita; Toshio Sato; Michie Aizawa; Misa Ki; Yumiko Kadoyama; Kenji Hirano; Satoko Kinjo; Hiroshi Asao; Keiko Kawamoto; Haruko Kariya; Sou-Ichi Makino; Takashi Hamabata; Kazutoshi Sawada; Ko Kato
Journal:  Transgenic Res       Date:  2010-10-24       Impact factor: 2.788

Review 2.  Immunotherapy of type 1 diabetes: where are we and where should we be going?

Authors:  Xunrong Luo; Kevan C Herold; Stephen D Miller
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

Review 3.  Tolerization against atherosclerosis using heat shock protein 60.

Authors:  Cecilia Wick
Journal:  Cell Stress Chaperones       Date:  2015-11-17       Impact factor: 3.667

4.  Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo.

Authors:  Jing Fang; Yong Lu; Kedong Ouyang; Guojun Wu; Huiyong Zhang; Yanhua Liu; Yingying Chen; Ming Lin; Huaqian Wang; Liang Jin; Rongyue Cao; Rouel S Roque; Li Zong; Jingjing Liu; Taiming Li
Journal:  Clin Vaccine Immunol       Date:  2009-05-20

5.  Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice.

Authors:  Yanjun Ma; Jingjing Liu; Jing Hou; Yuankai Dong; Yong Lu; Liang Jin; Rongyue Cao; Taiming Li; Jie Wu
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

6.  Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation.

Authors:  Huashan Gao; Qian Zhao; Shanshan Tang; Kaiying Li; Fujian Qin; Ziwei Song; Yi Pan; Liang Jin; Yanfeng Zhang
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.